PNC-27 vs Palmitoyl Tetrapeptide-7
Side-by-side comparison of key properties, dosing, and research.
Immune Support
PNC-27Skin & Cosmetic
Palmitoyl Tetrapeptide-7- Summary
- PNC-27 is a synthetic peptide derived from the p53 tumor suppressor protein, containing both an HDM2-binding domain and a transmembrane penetratin sequence. It selectively kills cancer cells by binding MDM2/HDM2 overexpressed on the plasma membrane of malignant cells, inducing membranolysis without harming normal cells.
- Palmitoyl Tetrapeptide-7 (Rigin) is a cosmetic peptide consisting of palmitic acid linked to the tetrapeptide sequence GQPR (Gly-Gln-Pro-Arg). It was designed to mimic the biological activity of the IgG immunoglobulin C-terminus, which downregulates the production of interleukin-6 (IL-6), a key driver of skin aging and inflammation.
- Half-Life
- Not well established; estimated minutes to hours
- Topical penetration-dependent; effects last hours to days
- Admin Route
- Intravenous (research), Intraperitoneal (research)
- Topical
- Research
- —
- —
- Typical Dose
- Not established for humans; research doses vary by cell line and model
- 2-5 ppm concentration in formulation
- Frequency
- Not established for human use
- Twice daily
- Key Benefits
- Selective cytotoxicity against cancer cells overexpressing HDM2/MDM2
- Spares normal cells lacking surface HDM2 expression
- Membranolytic mechanism bypasses intracellular resistance pathways
- Demonstrated activity against breast, pancreatic, leukemia, and melanoma cell lines
- Potential for combination with conventional chemotherapy
- Novel non-genotoxic anticancer mechanism
- Reduces IL-6 inflammatory cytokine in skin
- Prevents 'inflammaging' of the skin
- Inhibits MMP collagen-degrading enzymes
- Synergistic with Matrixyl for anti-aging
- Clinically tested for wrinkle and skin texture improvement
- Well-tolerated topically
- Side Effects
- Limited human clinical data; largely in vitro and animal studies
- Potential immunogenic reactions (foreign peptide)
- Systemic toxicity at high doses not well characterized
- Unknown interactions with current chemotherapy agents
- Contact sensitization (rare)
- Well-tolerated at standard concentrations
- Stacks With
- —
- —